Italy Dry Age Related Macular Degeneration (AMD) Market

ID: MRFR/LS/46828-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026
Italy Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Userss (hospitals & clinics, diagnostic centers, academic & research institutes) - Growth Outlook & Industry Forecast 2025 To 2035
Italy Dry Age Related Macular Degeneration (AMD) Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.47%
2024 Market Size$ 178.5 Million
2025 Market Size$ 193.62 Million
2035 Market Size$ 436.5 Million
Key Players
Regeneron Pharmaceuticals
Novartis
Roche
Bayer
Alcon
Amgen
Trends
  • Rising Awareness and Education
  • Technological Advancements in Treatment
  • Regulatory Support for Research
Opportunities
  • Increasing Aging Population
  • Rising Healthcare Expenditure
  • Advancements in Diagnostic Technologies
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Stages (USD Million)
      1. 4.1.1 Early Age-Related Macular Degeneration
      2. 4.1.2 Intermediate Age-Related Macular Degeneration
      3. 4.1.3 Late Age-Related Macular Degeneration
    2. 4.2 Chemicals and Materials, BY Age Group (USD Million)
      1. 4.2.1 Above 75 Years
      2. 4.2.2 Above 60 Years
      3. 4.2.3 Above 40 Years
    3. 4.3 Chemicals and Materials, BY Route of Administration (USD Million)
      1. 4.3.1 Oral
      2. 4.3.2 Injectables
    4. 4.4 Chemicals and Materials, BY End Users (USD Million)
      1. 4.4.1 Hospitals & Clinics
      2. 4.4.2 Diagnostic Centers
      3. 4.4.3 Academic & Research Institutes
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Regeneron Pharmaceuticals (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bayer (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Alcon (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Santen Pharmaceutical (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Horizon Therapeutics (IE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 ITALY MARKET ANALYSIS BY STAGES
    3. 6.3 ITALY MARKET ANALYSIS BY AGE GROUP
    4. 6.4 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 ITALY MARKET ANALYSIS BY END USERS
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY STAGES, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY STAGES, 2024 TO 2035 (USD Million)
    14. 6.14 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY END USERS, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY END USERS, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY STAGES, 2025-2035 (USD Million)
      2. 7.2.2 BY AGE GROUP, 2025-2035 (USD Million)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      4. 7.2.4 BY END USERS, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Italy Dry Age Related Macular Degeneration (AMD) Market Segmentation

Italy Dry Age Related Macular Degeneration (AMD) Market By Stages (USD Million, 2025-2035)

  • Early Age-Related Macular Degeneration
  • Intermediate Age-Related Macular Degeneration
  • Late Age-Related Macular Degeneration

Italy Dry Age Related Macular Degeneration (AMD) Market By Age Group (USD Million, 2025-2035)

  • Above 75 Years
  • Above 60 Years
  • Above 40 Years

Italy Dry Age Related Macular Degeneration (AMD) Market By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Injectables

Italy Dry Age Related Macular Degeneration (AMD) Market By End Users (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Academic & Research Institutes

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.